VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2001-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1023/A:1017994722130PMID 11678309
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EGF receptor expression, regulation, and function in breast cancer

  2004cited by this paper
• Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.

  1999cited by this paper
• Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design.

  1999cited by this paper
• PACAP (6–38) is a PACAP receptor antagonist for breast cancer cells

  1999cited by this paper
• Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

  1998cited by this paper
• Basic guide to the mechanisms of antiestrogen action.

  1998cited by this paper
• Tamoxifen in the Treatment of Breast Cancer

  1998cited by this paper
• (Stearyl, Norleucine17)VIP hybrid antagonizes VIP receptors on non-small cell lung cancer cells.

  1997cited by this paper
• Identification of VIP/PACAP receptors on rat astrocytes using antisense oligodeoxynucleotides

  1997cited by this paper
• Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy.

  1997cited by this paper
• Epidermal growth factor receptor family and chemosensitization.

  1997cited by this paper
• Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns.

  1997cited by this paper
• Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist.

  1996cited by this paper
• Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway.

  1996cited by this paper
• Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways

  1996cited by this paper
• Vasoactive Intestinal Peptide (VIP)1 Receptor

  1996cited by this paper
• Receptors for VIP, PACAP, Secretin, GRF, Glucagon, GLP‐1, and Other Members of Their New Family of G Protein‐Linked Receptors: Structure‐Function Relationship with Special Reference to the Human VIP‐1 Receptor a

  1996cited by this paper
• In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging.

  1995cited by this paper
• Mitogenic activity of neu differentiation factor/heregulin mimics that of epidermal growth factor and insulin‐like growth factor‐I in human mammary epithelial cells

  1995cited by this paper
• Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors.

  1995cited by this paper
• The biology of erbB-2/neu/HER-2 and its role in cancer.

  1994cited by this paper
• Multiple receptors for PACAP and VIP.

  1994cited by this paper
• A single autophosphorylation site confers oncogenicity to the Neu/ErbB‐2 receptor and enables coupling to the MAP kinase pathway.

  1994cited by this paper
• Vasoactive intestinal peptide: a growth promoter in neuroblastoma cells.

  1993cited by this paper
• Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor.

  1993cited by this paper
• Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos

  1993cited by this paper
• Differential signal transduction by five splice variants of the PACAP receptor

  1993cited by this paper
• A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.

  1993cited by this paper
• Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide.

  1992cited by this paper
• Cell biology. A signal chain of events.

  1992cited by this paper
• Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of research

  1992cited by this paper
• A signal chain of events

  1992cited by this paper
• An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system.

  1991cited by this paper
• Characterization of VIP- and helodermin-preferring receptors on human small cell lung carcinoma cell lines.

  1990cited by this paper
• Modulation of a 190-kD microtubule-associated protein in pigment epithelium by VIP.

  1989cited by this paper
• Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells.

  1988cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper
• Polypeptide with Broad Biological Activity: Isolation from Small Intestine

  1970cited by this paper
• [Malignant tumors of the breast].

  1960cited by this paper

• Effects of Static and Low‐Frequency Magnetic Fields on Gene Expression

  2025cites this paper
• Construction of a circRNA-miRNA-mRNA Regulatory Network for the Immune Regulation of Lung Adenocarcinoma

  2025cites this paper
• Construction of an immune-related gene prognostic model with experimental validation and analysis of immune cell infiltration in lung adenocarcinoma

  2024cites this paper
• Targeting the peripheral neural-tumour microenvironment for cancer therapy

  2024cites this paper
• Gene Expression Analysis Links Autocrine Vasoactive Intestinal Peptide and ZEB1 in Gastrointestinal Cancers

  2023cites this paper
• A safety study on ultra‑high or moderate static magnetic fields combined with platycodin D against lung cancer

  2023cites this paper
• Identification of the Diagnostic Biomarker VIPR1 in Hepatocellular Carcinoma Based on Machine Learning Algorithm

  2022cites this paper
• Comparing VIP and PD‐L1 expression as cancer biomarkers

  2022cites this paper
• A supramolecular nanofiber formed by enzyme-instructed self-assembly for SKBR-3 cell selective inhibition.

  2022cites this paper
• Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma

  2022cites this paper
• 748 Targeting vasoactive intestinal peptide receptor signaling in pancreatic ductal adenocarcinoma for enhanced anti-tumor response to checkpoint blockade

  2021cites this paper
• Endocrine regulation of cancer stem cell compartments in breast tumors.

  2021cites this paper
• Bombesin, endothelin, neurotensin and pituitary adenylate cyclase activating polypeptide cause tyrosine phosphorylation of receptor tyrosine kinases.

  2020cites this paper
• Peptide receptors as cancer drug targets

  2019cites this paper
• Mechanism of VIPR1 gene regulating human lung adenocarcinoma H1299 cells

  2019cites this paper
• Editorial: What's New in Endocrinology?

  2019cites this paper
• Neuropeptide G Protein-Coupled Receptors as Oncotargets

  2018cites this paper
• Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer

  2016cites this paper
• PACAP and VIP Inhibit the Invasiveness of Glioblastoma Cells Exposed to Hypoxia through the Regulation of HIFs and EGFR Expression

  2016cites this paper
• Neuropeptides as lung cancer growth factors.

  2015cites this paper
• Vasoactive intestinal peptide receptor-based imaging and treatment of tumors (Review).

  2014cites this paper
• Sensitizing the Therapeutic Efficacy of Taxol with Shikonin in Human Breast Cancer Cells

  2014cites this paper
• VIP/PACAP Receptors

  2013cites this paper
• Identification and optimization of small molecule antagonists of vasoactive intestinal peptide receptor-1 (VIPR1).

  2012cites this paper
• Changes in PACAP Immunoreactivity in Human Milk and Presence of PAC1 Receptor in Mammary Gland during Lactation

  2012cites this paper
• PYK-2 is Tyrosine Phosphorylated after Activation of Pituitary Adenylate Cyclase Activating Polypeptide Receptors in Lung Cancer Cells

  2012cites this paper
• Physical Activity and Natural Anti-VIP Antibodies: Potential Role in Breast and Prostate Cancer Therapy

  2011cites this paper
• Can natural antibodies to VIP or VIP-like HIV-1 glycoprotein facilitate prevention and supportive treatment of breast cancer?

  2011cites this paper
• The vasoactive intestinal peptide-receptor system is involved in human glioblastoma cell migration.

  2010cites this paper
• Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells.

  2009cites this paper
• Implication du système VIP-récepteurs dans la migration et l'invasion in vitro de cellules de glioblastome humain

  2009cites this paper
• VIP down‐regulates the inflammatory potential and promotes survival of dying (neural crest‐derived) corneal endothelial cells ex vivo: necrosis to apoptosis switch and up‐regulation of Bcl‐2 and N‐cadherin

  2009cites this paper
• Generation of PEGylated VPAC1-selective antagonists that inhibit proliferation of a lung cancer cell line.

  2008cites this paper
• VIP, From Gene to Behavior and Back: Summarizing my 25 Years of Research

  2008cites this paper
• VPAC receptors as target for anti-cancer drug delivery

  2008influential citation
• Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.

  2008cites this paper
• 1,1-Bis(3'-indolyl)-1-(p-biphenyl)methane inhibits basal-like breast cancer growth in athymic nude mice

  2007cites this paper
• Vasoactive intestinal peptide-camptothecin conjugates inhibit the proliferation of breast cancer cells.

  2007cites this paper
• Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells.

  2007cites this paper
• Effect of vasoactive intestinal peptide on gastric adenocarcinoma

  2007cites this paper
• Potential inhibition of the neuro-neoplastic interactions: the clue of a GPCR-targeted therapy.

  2007cites this paper
• Vasoactive intestinal peptide receptors: a molecular target in breast and lung cancer.

  2007cites this paper
• VIP and PACAP as Autocrine Growth Factors in Breast and Lung Cancer

  2006cites this paper
• VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice.

  2004cites this paper
• Immunocytochemical Identification of VPAC1, VPAC2, and PAC1 Receptors in Normal and Neoplastic Human Tissues with Subtype-Specific Antibodies

  2004cites this paper
• Clinical endocrinology and metabolism. Potential clinical applications of vasoactive intestinal peptide: a selected update.

  2004cites this paper
• VIP and drug design.

  2003cites this paper
• VIP as a trophic factor in the CNS and cancer cells.

  2003cites this paper
• Nonpeptide gastrin releasing peptide receptor antagonists inhibit the proliferation of lung cancer cells.

  2003cites this paper
• The Biological Significance of PACAP and PACAP Receptors in Human Tumors: From Cell Lines to Cancers

  2003cites this paper
• Peptide receptors as molecular targets for cancer diagnosis and therapy.

  2003cites this paper
• A vasoactive intestinal peptide receptor analog alters the expression of homeobox genes.

  2002cites this paper
• Comparison of an 18F labeled derivative of vasoactive intestinal peptide and 2-deoxy-2-[18F]fluoro-D-glucose in nude mice bearing breast cancer xenografts.

  2002cites this paper
• VIP-ellipticine derivatives inhibit the growth of breast cancer cells.

  2002cites this paper
• In vitro and in vivo treatment of colon cancer by VIP antagonists.

  2002cites this paper